Clinical trials: Olaparib
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
This is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or olaparib in participants with…
- Trial name
- NCT03923270
- Testing
- Durvalumab, Tremelimumab, Olaparib Pill
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs.
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
- Trial name
- NCT04739800
- Testing
- Biospecimen Collection, Cediranib Maleate, Computed Tomography
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency
Functional Analysis of BRCAness
PARP inhibitors are most effective in homologous recombinant (HR) deficient tumors. There are clear indications that besides BRCA1 or BRCA2 mutated EOC, there is an additional group of EOC having deficiencies in HR (i.e.
- Conditions
- Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- FAB (NCT04780945)
- Testing
- Functional RAD51 assay, Olaparib Oral Product
- Where
- 3 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Leiden University Medical Center
Pulmonary Arterial Hypertension
Olaparib for PAH: a Pilot Study
The main OBJECTIVE of this proposal is to extend our preclinical findings on the role of DNA damage and poly(ADP-ribose) polymerases (PARP) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH)…
- Trial name
- OPTION-p (NCT03251872)
- Testing
- Olaparib
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Laval University
Malignant Neoplasm of Breast, Breast Cancer
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
This study will examine the combination of pembrolizumab and olaparib in three populations. Cohort 1: aBC patients with a germline mutation in BRCA1 or BRCA2, cohort 2: aBC patients with a germline mutation in one of the moderate…
- Trial name
- COMPRENDO (NCT05033756)
- Testing
- Pembrolizumab Injection [Keytruda], Olaparib Oral Tablet [Lynparza]
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Institut fuer Frauengesundheit
Pancreatic Acinar Cell Carcinoma
Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
Background: Pancreatic Acinar Cell Carcinoma (PACC) is a rare pancreatic tumor. People with PACC usually present with advanced disease, and their prognosis is poor.
- Trial name
- NCT05286827
- Testing
- Olaparib, ECG, CT CAP
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer.
- Trial name
- RegeNovar (NCT07637851)
- Testing
- Ubamatamab, Chemotherapy, Bevacizumab
- Where
- 11 sites in France
- Volunteers
- 43 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovary Cancer
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs.
- Trial name
- NCT07667751
- Testing
- Sunitinib、Olaparib、Tolilizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Bai-Rong Xia
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains…
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT05554328
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 295 sites in United States, Puerto Rico
- Volunteers
- 165 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)
[Objectives] Objectives include following to capture safety and efficacy of LYNPARZA in actual clinical use. 1. ADR development in actual clinical use 2. Factors which may affect safety and efficacy 3.
- Trial name
- NCT03505307
- Volunteers
- 846 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants…
- Trial name
- KEYLYNK-010 (NCT03834519)
- Testing
- Pembrolizumab, Olaparib, Abiraterone acetate
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 793 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma, Recurrent Glioblastoma
Surgical Pembro +/- Olaparib w TMZ for rGBM
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT05463848
- Testing
- Pembrolizumab, Olaparib, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- L. Nicolas Gonzalez Castro, MD, PhD
Oral Squamous Cell Carcinoma (OSCC)
A Dye for the Detection of Cancer of the Tongue and Mouth
The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used to detect this type of cancer. This will be the first time that PARPi-FL is being tried in people.
- Trial name
- NCT03085147
- Testing
- Olaparib
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
- Trial name
- NCT05898399
- Testing
- ART6043, Olaparib
- Where
- 27 sites in United States, Spain and 1 more
- Volunteers
- 181 people
- Sponsor
- Artios Pharma Ltd
High Grade Serous Ovarian Cancer
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor".
- Trial name
- IDOL (NCT06976892)
- Testing
- Dose Level 2 (starting dose), Dose Level 1, Dose Level -1
- Where
- 3 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC)…
- Conditions
- Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II
- Trial name
- PLANET (NCT07486687)
- Testing
- Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib)
- Volunteers
- 1,000 people
- Sponsor
- The Netherlands Cancer Institute
Ovarian Cancer, Breast Cancer
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy.
- Trial name
- NCT04041128
- Testing
- Lynparza
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Glioblastoma, Glioblastoma Multiforme
Study of Pamiparib in Newly Diagnosed and rGBM
This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18).
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Trial name
- NCT04614909
- Testing
- Pamiparib, Olaparib, Radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nader Sanai
Ovarian Cancer
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and…
- Trial name
- DUETTE (NCT04239014)
- Testing
- Olaparib, Ceralasertib
- Where
- 26 sites in United States, Canada and 2 more
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer (mCRPC)
PROLONG (PRostateOLaparibONcombinationGcc) Study
The study will generate regionally relevant data to inform clinical practice, support treatment guidelines, and potentially contribute to supportive evidence for health authority discussions or scientific publications.
- Trial name
- PROLONG (NCT07674121)
- Testing
- Olaparib and Abiraterone Combination
- Volunteers
- 75 people
- Sponsor
- AstraZeneca